Get started
Author

Anneli Nilsson

ORCID: 0000-0002-2468-4035
Observed ORCID: 0000-0002-2468-4035
OpenAlex ID: A5021639097
First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies
2019 · Sandra M. M. Irenaeus, Dorte Nielsen, et al. · International Journal of Cancer · 135
Identification of the Antigenic Epitopes in Staphylococcal Enterotoxins A and E and Design of a Superantigen for Human Cancer Therapy
2003 · Eva Erlandsson, Kerstin Andersson, et al. · Journal of Molecular Biology · 29
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
2021 · Adnan Deronic, Anneli Nilsson, et al. · Cancer Immunology Immunotherapy · 20
PDF
The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2022 · Michelle H. Nelson, Sara Fritzell, et al. · Molecular Cancer Therapeutics · 11
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
2023 · Karin Enell Smith, Sara Fritzell, et al. · Cancer Immunology Immunotherapy · 10
PDF
851 Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4–1BB x 5T4 ADAPTIR™ bispecific antibody
2020 · Michelle Nelson, Robert Miller, et al. · Journal for ImmunoTherapy of Cancer · 3
Abstract 2380: Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
2019 · Anna Dahlman, Michelle Nelson, et al. · Cancer Research · 3
Abstract 2376: Mitazalimab, a potent CD40 agonist in combination with FOLFIRINOX demonstrates changes consistent with increased immune activation in TME and peripheral blood in a preclinical pancreatic cancer tumor model
2024 · Karin Enell Smith, David Gomez Jimenez, et al. · Cancer Research · 2
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al. · Cancer Immunology Research · 1
PDF
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
2023 · Ida Uddbäck, Sara Fritzell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 4155: Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells
2022 · Karin Enell Smith, Mia Thagesson, et al. · Cancer Research · 1
Abstract 1593: Mitazalimab, a potent CD40 agonist with potential for combination with chemotherapy
2021 · Adnan Deronic, Mia Thagesson, et al. · Cancer Research · 1
Data from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S1 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S17 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Table S2 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S7 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S19 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S21 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S8 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S16 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S14 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S5 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Table S1 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Works count: 48
Citation count: 217
H-index: 5
I10-index: 5
Year
Topic
Type